Mundipharma launches Pelmeg biosimilar in Europe

6 February 2019

Following European Commission approval last November, the Mundipharma network of independent associated companies today announced the launch of Pelmeg (pegfilgrastim), a biosimilar of Amgen’s (Nasdaq: AMGN) Neulasta.

Pelmeg is the fourth biosimilar medicine to be commercialised by Mundipharma, expanding its portfolio and commercial footprint across Europe. It was developed by Cinfa Biotech which was acquired by Mundipharma last year.

Novartis’(NOVN: VX) US generics business Sandoz also won European approval for its biosimilar Ziextenzo (pegfilgrastim), in November 2018. Neulasta generated global sales of $4.48 billion for Amgen in full-year 2018, as did Fulphila (MYL-1401H), which is produced by generics giant Pharmaceuticals (Nasdaq: MYL) and Indian biosimilars major Biocon

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK